Bio-Works Technologies AB (publ) (BIOWKS.ST)
SEK 1.36
(3.82%)
SEK 1.36
(3.82%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -56.82 Million SEK | -21.96% |
| 2022 | -44.95 Million SEK | -247.32% |
| 2021 | -12.94 Million SEK | 70.95% |
| 2020 | -44.54 Million SEK | -5.78% |
| 2019 | -42.11 Million SEK | -10.96% |
| 2018 | -37.95 Million SEK | -60.44% |
| 2017 | -23.65 Million SEK | -37.89% |
| 2016 | -17.15 Million SEK | -38.8% |
| 2015 | -12.36 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q2 | -28.77 Million SEK | -100.0% |
| 2023 Q3 | -14.02 Million SEK | 51.27% |
| 2023 Q4 | -14.02 Million SEK | 0.0% |
| 2023 FY | -54.82 Million SEK | -21.96% |
| 2023 Q1 | -14.38 Million SEK | 33.06% |
| 2022 Q4 | -21.49 Million SEK | -100.71% |
| 2022 Q2 | -23.53 Million SEK | -100.0% |
| 2022 Q1 | -11.76 Million SEK | 46.08% |
| 2022 FY | -44.95 Million SEK | -247.32% |
| 2022 Q3 | -10.7 Million SEK | 54.49% |
| 2021 Q2 | 8.87 Million SEK | 100.0% |
| 2021 FY | -12.94 Million SEK | 70.95% |
| 2021 Q1 | 4.43 Million SEK | 137.16% |
| 2021 Q4 | -21.82 Million SEK | -100.0% |
| 2021 Q3 | -10.91 Million SEK | -222.89% |
| 2020 Q3 | -11.94 Million SEK | -21.6% |
| 2020 Q2 | -9.82 Million SEK | 13.1% |
| 2020 Q1 | -11.3 Million SEK | 43.95% |
| 2020 FY | -44.54 Million SEK | -5.78% |
| 2020 Q4 | -11.94 Million SEK | 0.0% |
| 2019 Q2 | -11.55 Million SEK | -11.23% |
| 2019 Q1 | -10.39 Million SEK | 52.28% |
| 2019 FY | -42.11 Million SEK | -10.96% |
| 2019 Q4 | -20.16 Million SEK | -76.94% |
| 2019 Q3 | -11.39 Million SEK | 1.38% |
| 2018 Q2 | -8.84 Million SEK | -20.67% |
| 2018 FY | -37.95 Million SEK | -60.44% |
| 2018 Q4 | -21.77 Million SEK | -175.48% |
| 2018 Q3 | -7.9 Million SEK | 10.68% |
| 2018 Q1 | -7.33 Million SEK | 21.07% |
| 2017 Q3 | -4.21 Million SEK | 16.93% |
| 2017 Q1 | -5.07 Million SEK | 11.46% |
| 2017 FY | -23.65 Million SEK | -37.89% |
| 2017 Q4 | -9.29 Million SEK | -120.37% |
| 2017 Q2 | -5.07 Million SEK | 0.0% |
| 2016 Q4 | -5.73 Million SEK | 0.0% |
| 2016 FY | -17.15 Million SEK | -38.8% |
| 2015 FY | -12.36 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Asarina Pharma AB (publ) | -12.82 Million SEK | -342.945% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 81.726% |
| NextCell Pharma AB | -41.95 Million SEK | -35.418% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -246.512% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 85.362% |
| AcouSort AB (publ) | -17.08 Million SEK | -232.5% |
| OncoZenge AB (publ) | -15.9 Million SEK | -257.32% |
| Xintela AB (publ) | -54.08 Million SEK | -5.063% |
| Ziccum AB (publ) | -21.41 Million SEK | -165.37% |
| Active Biotech AB (publ) | -45.8 Million SEK | -24.063% |
| Alzinova AB (publ) | -16.48 Million SEK | -244.788% |
| Amniotics AB (publ) | -30.87 Million SEK | -84.065% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 77.142% |
| BioArctic AB (publ) | 229.24 Million SEK | 124.786% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 87.811% |
| Camurus AB (publ) | 431.44 Million SEK | 113.17% |
| Cantargia AB (publ) | -280.02 Million SEK | 79.709% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -169.409% |
| CombiGene AB (publ) | -35.66 Million SEK | -59.317% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 62.581% |
| Genovis AB (publ.) | 61.5 Million SEK | 192.392% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 49.859% |
| Mendus AB (publ) | -101.61 Million SEK | 44.084% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -53.276% |
| Kancera AB (publ) | -64.88 Million SEK | 12.434% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 1154.976% |
| LIDDS AB (publ) | -40.2 Million SEK | -41.325% |
| Lipum AB (publ) | -37.17 Million SEK | -52.835% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -368.511% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 566.932% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -217.489% |
| Saniona AB (publ) | -95.81 Million SEK | 40.694% |
| Simris Alg AB (publ) | -37.3 Million SEK | -52.315% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 68.374% |
| Intervacc AB (publ) | -102.85 Million SEK | 44.755% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -12872.831% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -243.89% |
| Corline Biomedical AB | -1.8 Million SEK | -3041.017% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 68.049% |
| Aptahem AB (publ) | -11.11 Million SEK | -411.308% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 53.83% |
| Fluicell AB (publ) | -26.55 Million SEK | -113.983% |
| Biovica International AB (publ) | -124.82 Million SEK | 54.479% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -34.574% |
| Abliva AB (publ) | -95.5 Million SEK | 40.507% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 82.618% |
| 2cureX AB (publ) | -32.51 Million SEK | -74.737% |
| I-Tech AB | 20.2 Million SEK | 381.25% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 93.168% |
| Cyxone AB (publ) | -22.98 Million SEK | -147.166% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 37.833% |
| Biosergen AB | -27.03 Million SEK | -110.16% |
| Nanologica AB (publ) | -75.15 Million SEK | 24.397% |
| SynAct Pharma AB | -215.81 Million SEK | 73.671% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -28.98% |
| BioInvent International AB (publ) | -330.3 Million SEK | 82.797% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -139.377% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 77.19% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -472.215% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 48.008% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -386.564% |